TOKYO, Japan,

BIOTRONIK Launches Next Generation Injectable Cardiac Monitor in Japan

BIOMONITOR III Makes Injection, Monitoring and Diagnosis of Arrhythmias Easy and Efficient

BIOTRONIK this month announced the market release of its new injectable cardiac monitor (ICM), BIOMONITOR III. The novel device is designed to help patients with irregular heart rhythms by documenting unexplained syncope with increased clarity.

As the most common type of arrhythmia, 33.5 million patients worldwide suffer from atrial fibrillation (AF).1 It is associated with a five-fold increase in risk of stroke, a three-fold increase in incidence of congestive heart failure, and higher mortality.2 Aiming to improve the accuracy of arrhythmia detection and diagnosis, BIOTRONIK’s new ICM offers increased signal quality.3

“The key feature with this new device is the long vector design which potentially captures not only the ventricular but also the atrial waves on the subcutaneous ECG which can provide a more accurate diagnosis,” said Dr. Noritoshi Ito from Kawasaki Saiwai Hospital in Kanagawa, Japan.

BIOMONITOR III’s unique BIOvector is designed to deliver high definition signals. As a result, the high signal amplitudes and visibility of the p-waves3 make it easier for the physician to confidently evaluate arrhythmias.

BIOTRONIK’s next generation ICM comes ready to inject, with the device pre assembled in a one-step injection tool. To optimize patient comfort, BIOMONITOR III offers a very small size and flexible sensing antenna. The device is injected under the skin with a very small incision, allowing for a quick and easy injection procedure.

BIOMONITOR III works with BIOTRONIK’s fully automated, ‘plug in and go’ Home Monitoring. Due to automatic pairing, initialization and data transmission no active patient involvement is required. The new product also features Intelligent Memory Management, which prevents the overwriting of clinically relevant episodes. Thus, no relevant information is missed.

“We are very excited about the launch of BIOMONITOR III as a key addition to our product portfolio here in Japan,” commented Jeffrey Annis, Regional Vice President at BIOTRONIK Japan. “It provides medical staff with a reliable tool to identify underlying arrhythmias thus allowing physicians to adjust their therapeutic approach and improve the overall care for their patients.”


1 Chugh SS et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation, 129 (2014):837-847.

2 Camm AJ et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747.




At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular and endovascular solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.